Personalis (NASDAQ:PSNL) Shares Gap Down Following Insider Selling

Shares of Personalis, Inc. (NASDAQ:PSNL) gapped down before the market opened on Monday after an insider sold shares in the company. The stock had previously closed at $10.73, but opened at $10.10. Personalis shares last traded at $9.89, with a volume of 519,002 shares.

Specifically, CFO Aaron Tachibana sold 103,668 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the transaction, the chief financial officer owned 164,458 shares in the company, valued at $1,772,857.24. This represents a 38.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on PSNL shares. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Needham & Company LLC increased their target price on shares of Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Guggenheim lifted their price target on shares of Personalis from $6.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Morgan Stanley upped their price objective on shares of Personalis from $5.00 to $9.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Finally, Lake Street Capital reiterated a “buy” rating and set a $11.00 target price on shares of Personalis in a research report on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Personalis currently has an average rating of “Moderate Buy” and an average price target of $10.29.

Personalis Stock Down 8.9%

The company has a 50-day moving average price of $8.38 and a two-hundred day moving average price of $6.58. The stock has a market capitalization of $868.46 million, a P/E ratio of -11.12 and a beta of 1.99.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The company had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $13.31 million. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts expect that Personalis, Inc. will post -1.4 earnings per share for the current year.

Institutional Trading of Personalis

Several institutional investors and hedge funds have recently modified their holdings of the business. Oracle Investment Management Inc. purchased a new position in Personalis during the 3rd quarter valued at $1,496,000. XTX Topco Ltd bought a new stake in Personalis during the third quarter worth about $539,000. Millennium Management LLC grew its holdings in Personalis by 11.0% in the third quarter. Millennium Management LLC now owns 1,210,754 shares of the company’s stock worth $7,894,000 after purchasing an additional 120,027 shares during the period. Brevan Howard Capital Management LP bought a new position in shares of Personalis during the third quarter valued at approximately $97,000. Finally, Brooklyn Investment Group purchased a new position in shares of Personalis during the third quarter valued at approximately $723,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.